Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

AI Briefing

• – Agilent to showcase precision oncology and digital pathology advances at USCAP 2026, highlighting expanded biomarker testing capabilities and digital pathology adoption.
• – Agilent to feature its Dako Omnis family of instruments as a foundational tool in the evolving field of precision oncology.
• – Agilent to demonstrate its commitment to advancing cancer research and treatment through innovative technology solutions.